Briacell Therapeutics Corp Stock Performance
| BCTX Stock | USD 0.53 0.03 5.54% |
On a scale of 0 to 100, Briacell Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of -0.0908, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Briacell Therapeutics are expected to decrease at a much lower rate. During the bear market, Briacell Therapeutics is likely to outperform the market. Please check Briacell Therapeutics' sortino ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Briacell Therapeutics' price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Briacell Therapeutics Corp are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Briacell Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:300 | Dividend Date 2020-01-02 | Last Split Date 2020-01-02 |
1 | BriaCell Therapeutics Corp. Sees Large Increase in Short Interest | 09/27/2024 |
2 | BriaCell stock gains after trial update | 10/15/2024 |
3 | Disposition of 50000 shares by Embro-pantalony Vaughn C. of Briacell Therapeutics at 8.47 subject to Rule 16b-3 | 11/13/2024 |
4 | BriaCell Therapeutics slumps 29, prices 5.55M stock offering | 12/12/2024 |
5 | BriaCell Therapeutics Announces Closing of 5.5 Million Public Offering | 12/13/2024 |
6 | Disposition of 50000 shares by Schmieg Martin E. of Briacell Therapeutics at 8.47 subject to Rule 16b-3 | 12/20/2024 |
| Begin Period Cash Flow | 21.3 M |
Briacell |
Briacell Therapeutics Relative Risk vs. Return Landscape
If you would invest 63.00 in Briacell Therapeutics Corp on September 24, 2024 and sell it today you would lose (8.91) from holding Briacell Therapeutics Corp or give up 14.14% of portfolio value over 90 days. Briacell Therapeutics Corp is currently generating 0.5507% in daily expected returns and assumes 12.5398% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Briacell, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Briacell Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Briacell Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Briacell Therapeutics Corp, and traders can use it to determine the average amount a Briacell Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0439
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BCTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.54 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.55 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Briacell Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Briacell Therapeutics by adding it to a well-diversified portfolio.
Briacell Therapeutics Fundamentals Growth
Briacell Stock prices reflect investors' perceptions of the future prospects and financial health of Briacell Therapeutics, and Briacell Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Briacell Stock performance.
| Return On Equity | -2.06 | ||||
| Return On Asset | -1.26 | ||||
| Current Valuation | 19.84 M | ||||
| Shares Outstanding | 44.2 M | ||||
| Price To Book | 6.13 X | ||||
| EBITDA | (4.77 M) | ||||
| Net Income | (4.93 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 8.56 M | ||||
| Current Ratio | 45.00 X | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (24.13 M) | ||||
| Earnings Per Share | (0.89) X | ||||
| Market Capitalization | 25.47 M | ||||
| Total Asset | 5.87 M | ||||
| Retained Earnings | (85.44 M) | ||||
| Working Capital | (3.81 M) | ||||
About Briacell Therapeutics Performance
Evaluating Briacell Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Briacell Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Briacell Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 90.9 K | 95.5 K | |
| Return On Tangible Assets | (0.68) | (0.64) | |
| Return On Capital Employed | (1.06) | (1.11) | |
| Return On Assets | (0.67) | (0.64) | |
| Return On Equity | 4.84 | 5.08 |
Things to note about Briacell Therapeutics performance evaluation
Checking the ongoing alerts about Briacell Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Briacell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Briacell Therapeutics is way too risky over 90 days horizon | |
| Briacell Therapeutics has some characteristics of a very speculative penny stock | |
| Briacell Therapeutics appears to be risky and price may revert if volatility continues | |
| Briacell Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (4.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Briacell Therapeutics Corp currently holds about 41.04 M in cash with (24.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Briacell Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: BriaCell Therapeutics Announces Closing of 5.5 Million Public Offering |
- Analyzing Briacell Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Briacell Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Briacell Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Briacell Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Briacell Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Briacell Therapeutics' stock. These opinions can provide insight into Briacell Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.